echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Pharmaceutical company's 900 million acquisition of "explosive thunder", an inflated 170 million profit was fined!

    Pharmaceutical company's 900 million acquisition of "explosive thunder", an inflated 170 million profit was fined!

    • Last Update: 2021-07-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network News, March 19, recently, Asia Pacific Pharmaceuticals released a 2020 performance bulletin, with an estimated net profit of 27.
    27 million yuan, a year-on-year increase of 101.
    32%, realizing a turnaround from loss to profit
    .
    Subsequently, the company received the "Advance Notice of Administrative Penalties and Market Banning" issued by the China Securities Regulatory Commission.
    From 2016 to 2018, its subsidiary Shanghai Xinfengfeng finance fraud, and proposed to impose a fine of 600,000 yuan on Asia-Pacific Pharmaceuticals.
    At that time, Shanghai Xinfengfeng The chairman and general manager Ren Jun and the chairman of Asia Pacific Pharmaceuticals Chen Yaogen were fined 300,000 yuan and banned from entering the securities market for five years
    .
    According to statistics, more than 200 A-share pharmaceutical companies have disclosed their performance in 2020.
    Among them, 23 have turned losses into profits.
    9 companies including Ruikang Pharmaceutical, Meikang Biological, and Longjin Pharmaceutical have all lost their first losses in 2019
    .
    Yuheng Pharmaceutical and Asia-Pacific Pharmaceuticals "turned over" after a huge loss of 2 billion yuan; Ruikang Pharmaceutical went from a loss of 900 million yuan to a profit of 400 million yuan; Sunflower divested its loss-making business and transformed its pharmaceutical industry into a turnaround
    .

    Pharmaceutical companies 9 billion acquisition of "mine explosion" inflated 1.
    7 Yi profits fined
    a few days ago, the Asia-Pacific Pharmaceutical released results of Letters in 2020, the company achieved revenues of 515 million yuan, down 27.
    41%, mainly to Shanghai is no longer a new peak of biological medicine Co.
    , Ltd.
    and its subsidiaries were included in the company’s consolidated financial statements and due to the decrease in sales income affected by the epidemic; net profit was 27.
    27 million yuan, a year-on-year increase of 101.
    32%, and the performance turned around, mainly due to the company’s Keqiao factory house demolition compensation , The net profit loss in 2019 exceeded 2 billion yuan
    .
    After disclosing the performance report, Asia Pacific Pharmaceuticals received the "Administrative Penalty and Market Ban Advance Notice" issued by the China Securities Regulatory Commission.
    Shanghai New Peak has inflated its operating revenues of 454 million yuan and inflated operating costs by 2.
    75 since 2016-2018.
    100 million yuan, with an inflated total profit of 170 million yuan.
    After the above financial data was included in the consolidated statements of Asia Pacific Pharmaceutical, the company’s 2016-2018 annual report financial data and related disclosures were falsely recorded
    .
    The China Securities Regulatory Commission intends to order corrections, give warnings, and impose a fine of 600,000 yuan on Asia Pacific Pharmaceuticals; Ren Jun, then chairman and general manager of Shanghai New Peak, and Chen Yaogen, chairman of Asia Pacific Pharmaceuticals, were fined 300,000 yuan and banned for five years.
    stock market punishment
    .
    According to data, at the end of 2015, Asia Pacific Pharmaceuticals acquired 100% of Shanghai Xinfengfeng with 900 million yuan in cash in order to expand its CRO business.
    Shanghai Xinfengfeng became a wholly-owned subsidiary of Asia Pacific Pharmaceuticals and included it in the scope of consolidated statements
    .
    On March 6, Asia-Pacific Pharmaceuticals disclosed that the Asia-Pacific convertible bond credit rating of the company’s publicly issued convertible corporate bonds in 2019 was downgraded from A- to BBB
    .
    On March 9, the Zhejiang Provincial Department of Finance disclosed an administrative processing decision.
    The inspection team has conducted on-site inspections to inspect the quality of accounting information of Asia Pacific Pharmaceuticals in 2018 from June 2019.
    The inspection found that Issues such as untrue original vouchers for reimbursement of sales expenses, and irregularities in the contract attached to the promotion service fee
    .
    On March 11, Asia-Pacific Pharmaceuticals issued an announcement on the progress of house demolition compensation.
    The company received the second demolition compensation payment of 40 million yuan from the entrusted party, Keqiao District, Keqiao District, Shaoxing City.
    As of the announcement date, A total of 186.
    3 million yuan has been received for demolition compensation
    .
    As of the close of March 18, Asia Pacific Pharmaceutical's share price was 3.
    60 yuan, a drop of more than 80% compared with the high point before the thunderstorm in 2019
    .

      Yuheng, Ruikang.
    .
    .
    23 pharmaceutical companies turned losses into profits, and 9
    A-share pharmaceutical companies that “ turned around ” after their first losses.
    Note: Asia Pacific Pharmaceuticals and Jinghua Pharmaceutical are performance reports, and Guanhao Bio is the annual report.
    , And the rest are performance forecasts.
    Among the 23 pharmaceutical companies that have turned losses into profits, 9 companies including Ruikang Pharmaceutical, Meikang Biologics, and Longjin Pharmaceutical all lost their first losses in 2019
    .
    Yuheng Pharmaceutical and Asia-Pacific Pharmaceuticals "turned over" after a huge loss of 2 billion yuan; Ruikang Pharmaceutical went from a loss of 900 million yuan to a profit of 400 million yuan
    .
    Yuheng Pharmaceutical: The estimated net profit in 2020 is 380 million to 420 million yuan, a year-on-year increase of 114.
    28% to 115.
    78%, and the first loss of net profit in 2019 exceeds 2.
    5 billion yuan
    .
    According to Yuheng Pharmaceutical’s announcement, the company’s net profit attributable to shareholders of listed companies in 2020 increased significantly over the same period of the previous year, mainly due to the impact of non-recurring gains and losses.
    Among them, the company confirmed the sale of Aonuo (China) Pharmaceutical Co.
    , Ltd.
    Due to the relevant income obtained from 100% of the equity, it is estimated that the impact of the investment profit and loss of this sale on the net profit is about 687 million yuan
    .
    Ruikang Pharmaceutical: The estimated net profit in 2020 is 300 million to 400 million yuan, an increase of 132.
    33% to 143.
    11% year-on-year, and the net profit loss in 2019 will exceed 900 million yuan
    .
    Regarding the performance "turnover", Ruikang Pharmaceutical said that due to the impact of the new crown epidemic and the macro economy, the company's business development has declined compared with 2019.
    It is expected that the operating income of 2020 will be 26 to 30 billion yuan
    .
    In addition, the net value of goodwill has been significantly reduced compared to 2019, and there will be no significant impairment of goodwill; the net cash flow from operating activities in 2020 will be positive, and it will continue to improve quarter by quarter
    .
    On the same day when the performance announcement was released, Ruikang Pharmaceutical disclosed that the company plans to invest 320 million yuan to subscribe for 79.
    8% of Shandong Lekang Jinyue Industrial Co.
    , Ltd.
    through capital increase and share expansion.
    The investment funds are mainly used to supplement the liquidity of the target company
    .
    After the completion of this investment, the company will further improve the platform construction in the field of health , promote the AstraZeneca Innovation Center and other high-quality innovative medical projects to land in Lekang Jinyue Industrial Park, and continue to promote the integration of medical and health ecological resources
    .
    Meikang Bio: It is estimated that the net profit in 2020 will be 310 million to 350 million yuan, a year-on-year increase of 155.
    37% to 162.
    51%, and the net profit loss in 2019 will exceed 500 million yuan
    .
    Meikang said that on the one hand, affected by the new crown epidemic in 2020, the company's production and operation in the second quarter began to gradually resume
    .
    At the same time, the company's new coronavirus pneumonia detection service income and overseas sales of new coronavirus pneumonia detection products will have a positive impact on the operating performance in 2020; due to the transfer of the agency business of the subsidiary Hangzhou Yitian Biotechnology Co.
    , Ltd.
    , the company's agency business income Significant decline, the company's 2020 operating income fell by about 25% compared with the same period last year
    .
    On the other hand, the company's net value of goodwill has dropped significantly year-on-year, and there will be no large-scale impairment of goodwill
    .
    In addition, the company focuses on developing its core business of self-produced products, relying on its advantages in the field of biochemical reagents, continues to strengthen product R&D innovation and marketing development capabilities, and accelerates the layout of the instrument industry to achieve "diagnostic equipment as the engine, diagnostic products + diagnostics" With the coordinated development of "services", the company's self-produced products' revenue share and the company's overall profitability have increased
    .
    It is estimated that the impact of non-recurring gains and losses on net profit is about 175 million yuan, mainly due to the adjustment of the transaction consideration of the company's acquisition of Hangzhou Yitian Biotechnology Co.
    , Ltd.
    and the receipt of government subsidies
    .
    Sunflower: Net profit in 2020 is expected to be 36 million to 50 million yuan, an increase of 131.
    32% to 143.
    5% year-on-year, and a net profit loss of 115 million yuan in 2019
    .
    Sunflower said that the company has divested its original loss-making photovoltaic-related business on December 31, 2019.
    In 2020, the company’s main business has transformed from traditional photovoltaic business to the pharmaceutical field.
    The current main operating income is anti-infective drugs and anti-hypertensive drugs.
    Wait for sales revenue
    .
    Due to the divestiture of related businesses, the original photovoltaic-related loss-making subsidiary will no longer be included in the scope of the consolidated statement in 2020
    .
    According to the data, the owner's business of Zhejiang Beide Pharmaceutical, a subsidiary of Sunflower Holdings, is the research and development, production and sales of anti-infective and anti-hypertensive drugs.
    Its leading products cover anti-infective drugs and anti-hypertensive fields
    .
    As of the first half of 2020, Beide Pharmaceuticals has obtained a total of 22 preparations and API production approval documents, of which 2 varieties have been included in the Class A medical insurance catalogue, and 3 varieties have been included in the national essential medicine catalogue
    .
    Among them, clarithromycin raw materials account for the main component of revenue, and are sold to domestic production of clarithromycin preparationsPharmaceutical production enterprises , overseas sales area in India, South Korea, Spain, Pakistan and other countries
    .
    Source: Oriental Fortune.
    com, Announcement of Listed Companies
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.